Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Xalatan approved in E.U. as first-line therapy for lowering IOP in glaucoma patients

April 24, 2002

ISTA to proceed with Vitrase NDA filing

April 12, 2002

Third phase III trial under way for INS-365 Ophthalmic in dry eye

April 9, 2002

Antiangiogenic effects demonstrated for CA4P in mouse model of proliferative retinopathy

April 4, 2002

Sucampo licenses development and marketing rights to eye drop formulation of tacrolimus

April 2, 2002

ISTA reports preliminary phase III results for Vitrase

March 28, 2002

ISTA updates clinical progress of Vitrase

March 19, 2002

Inhibition of iNOS provides neuroprotection in glaucoma

March 11, 2002

Functional and morphological effects of Epitalon in rat model of retinitis pigmentosa

March 11, 2002

Russian research yields polypeptide complex with efficacy in exudative AMD

March 11, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...